Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.200
+0.020 (1.69%)
Jun 8, 2026, 4:00 PM EDT - Market closed
Entera Bio Employees
As of March 31, 2026, Entera Bio had 22 total employees, including 20 full-time and 2 part-time employees. The number of employees increased by 2 or 10.00% compared to the same quarter last year.
Employees
22
Change
2
Growth
10.00%
Revenue / Employee
n/a
Profits / Employee
-$562,591
Market Cap
59.07M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 22 | 2 | 10.00% | 20 | 2 |
| Dec 31, 2025 | 22 | 2 | 10.00% | 20 | 2 |
| Sep 30, 2025 | 22 | 2 | 10.00% | 20 | 2 |
| Jun 30, 2025 | 21 | 2 | 10.53% | 19 | 2 |
| Mar 31, 2025 | 20 | 1 | 5.26% | 18 | 2 |
| Dec 31, 2024 | 20 | 2 | 11.11% | 18 | 2 |
| Sep 30, 2024 | 20 | -1 | -4.76% | 18 | 2 |
| Jun 30, 2024 | 19 | -2 | -9.52% | 17 | 2 |
| Mar 31, 2024 | 19 | 1 | 5.56% | 17 | 2 |
| Dec 31, 2023 | 18 | 1 | 5.88% | 17 | 1 |
| Sep 30, 2023 | 21 | 2 | 10.53% | 19 | 2 |
| Jun 30, 2023 | 21 | -1 | -4.55% | 19 | 2 |
| Mar 31, 2023 | 18 | -3 | -14.29% | 18 | 0 |
| Dec 31, 2022 | 17 | -3 | -15.00% | 15 | 2 |
| Sep 30, 2022 | 19 | -4 | -17.39% | 19 | 0 |
| Jun 30, 2022 | 22 | 3 | 15.79% | 22 | 0 |
| Mar 31, 2022 | 21 | 2 | 10.53% | 21 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 139 |
| Acrivon Therapeutics | 76 |
| PMV Pharmaceuticals | 54 |
| PDS Biotechnology | 21 |
| Veru Inc. | 20 |
| Filana Therapeutics | 20 |
| Instil Bio | 17 |
| ImageneBio | 17 |
ENTX News
- 5 days ago - Entera Bio Proxy statement: Proxy filing - Filings
- 5 days ago - Entera Bio Proxy statement: Proxy filing - Filings
- 11 days ago - Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation - GlobeNewsWire
- 25 days ago - Entera Bio Proxy statement: Proxy filing - Filings
- 4 weeks ago - Entera Bio files to sell 19.57M ordinary shares for holders - TheFly
- 4 weeks ago - Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs - GlobeNewsWire
- 4 weeks ago - Entera Bio Registration statement: Registration filing - Filings
- 4 weeks ago - Entera Bio Quarterly report: Q1 2026 - Filings